Arsene Bienvenu Loembé

Arsene Bienvenu Loembé

UNVERIFIED PROFILE

Are you Arsene Bienvenu Loembé?   Register this Author

Register author
Arsene Bienvenu Loembé

Arsene Bienvenu Loembé

Publications by authors named "Arsene Bienvenu Loembé"

Are you Arsene Bienvenu Loembé?   Register this Author

6Publications

242Reads

48Profile Views

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).

Lung Cancer 2018 06 9;120:27-33. Epub 2018 Mar 9.

Department of Oncology, University College London Cancer Institute, London, UK; University College London Hospitals NHS Foundation Trust, London, UK. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002183029
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2018.03.007DOI Listing
June 2018

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

J Clin Oncol 2017 Nov 11;35(31):3591-3600. Epub 2017 Sep 11.

Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.9012DOI Listing
November 2017